|
gptkbp:instanceOf
|
gptkb:cancer
Gynecological cancer
|
|
gptkbp:affects
|
gptkb:Uterus
Endometrium
|
|
gptkbp:canBeMalignant
|
Yes
|
|
gptkbp:canBeSporadic
|
Yes
|
|
gptkbp:canMetastasizeTo
|
gptkb:bone
Lungs
Liver
Lymph nodes
|
|
gptkbp:diagnosedBy
|
Dilation and curettage
Endometrial biopsy
Transvaginal ultrasound
|
|
gptkbp:firstDescribed
|
19th century
|
|
gptkbp:hereditary
|
Yes
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Endometrial cancer
|
|
gptkbp:ICD-10_code
|
gptkb:C54.1
|
|
gptkbp:incidenceInUS
|
~66,000 new cases per year (2023)
|
|
gptkbp:isHormoneDependent
|
Often
|
|
gptkbp:isMostCommonGynecologicalCancerIn
|
gptkb:United_States
|
|
gptkbp:medianAge
|
60 years
|
|
gptkbp:mortalityInUS
|
~13,000 deaths per year (2023)
|
|
gptkbp:mostCommonType
|
gptkb:Endometrioid_adenocarcinoma
|
|
gptkbp:otherTypes
|
gptkb:Clear_cell_carcinoma
gptkb:Carcinosarcoma
gptkb:Serous_carcinoma
|
|
gptkbp:prevention
|
physical activity
Weight management
Oral contraceptive use
|
|
gptkbp:prognosis
|
Histological grade
Lymph node involvement
Stage at diagnosis
Patient age
|
|
gptkbp:rareIn
|
Women under 40
|
|
gptkbp:riskFactor
|
gptkb:Lynch_syndrome
gptkb:Polycystic_ovary_syndrome
Diabetes
Obesity
Hypertension
Early menarche
Estrogen exposure
Late menopause
Nulliparity
Tamoxifen use
|
|
gptkbp:screeningRecommendedFor
|
Women with Lynch syndrome
|
|
gptkbp:stageName
|
gptkb:FIGO_staging
gptkb:AJCC_staging
|
|
gptkbp:symptom
|
Weight loss
Abnormal uterine bleeding
Pelvic pain
Postmenopausal bleeding
|
|
gptkbp:treatment
|
radiation therapy
Surgery
Chemotherapy
Hormone therapy
Hysterectomy
|
|
gptkbp:bfsParent
|
gptkb:Clear_cell_carcinoma
gptkb:Womb
|
|
gptkbp:bfsLayer
|
6
|